๐ฌ Current Disease Focus:
Task Progress: 0%
๐ฅ Active Problem Solvers
0
๐ Experts collaborating globally
โก Current Task Assignment
๐งฌ Genetic Analysis
๐ Matching experts to specific tasks
๐ Resource Allocation by Research Phase:
๐ Data Analysis
๐งช Experimental Design
๐ฌ Clinical Trials
๐ Treatment Development
For the first phase of this study (phase I), the purpose will be to find th...
Status
Completed
Location
BCCA - Vancouver Cancer Centre
Start Date
2012-09-06
Trial ID
NCT01591421
Treatments Being Tested
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion cl...
Status
Recruiting
Location
Arizona Oncology Associates
Start Date
2020-07-14
Trial ID
NCT04485013
SBRT Combined with CAPEOX, Bevacizumab, and PD-1 Inhibitor in RAS-Mutant, M...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2025-02
Trial ID
NCT06835179
Treatments Being Tested
Evaluate the safety and antitumor activity of JYP0015 in adults with specif...
Status
Recruiting
Location
Beijing Cancer Hospital
Start Date
2025-03-31
Trial ID
NCT06895031
Treatments Being Tested
This is a prospective, multicenter, randomized controlled, phase II study. ...
Status
Not Yet Recruiting
Location
Sun Yat-sen University Cancer Center
Start Date
2026-06-01
Trial ID
NCT07621497
This phase I/II trial studies the best dose and side effects of glutaminase...
Status
Completed
Location
Vanderbilt-Ingram Cancer Center
Start Date
2017-08-23
Trial ID
NCT03263429
This study aimed to evaluate the effectiveness, safety, and cost-effectiven...
Status
Unknown
Location
Yonsei University Wonju College of Medicine
Start Date
2022-02-18
Trial ID
NCT05329727
This ComboMATCH patient screening trial is the gateway to a coordinated set...
Status
Recruiting
Location
University of Alabama at Birmingham Cancer Center
Start Date
2023-04-07
Trial ID
NCT05564377
Treatments Being Tested
This Expanded Access Program (EAP) is intended to provide daraxonrasib to e...
Status
Available
Location
Alabama Oncology
Start Date
TBD
Trial ID
NCT07573215
Treatments Being Tested
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib...
Status
Active Not Recruiting
Location
University of Alabama at Birmingham Cancer Center
Start Date
2023-04-25
Trial ID
NCT05554328